- Home
- AGIO vs GOF Comparison
AGIO vs GOF Comparison
Compare AGIO & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- GOF
- Stock Information
- Founded
- AGIO 2007
- GOF 2006
- Country
- AGIO United States
- GOF United States
- Employees
- AGIO N/A
- GOF N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- GOF Finance/Investors Services
- Sector
- AGIO Health Care
- GOF Finance
- Exchange
- AGIO Nasdaq
- GOF Nasdaq
- Market Cap
- AGIO 2.4B
- GOF 2.7B
- IPO Year
- AGIO 2013
- GOF N/A
- Fundamental
- Price
- AGIO $43.24
- GOF $13.55
- Analyst Decision
- AGIO Strong Buy
- GOF
- Analyst Count
- AGIO 4
- GOF 0
- Target Price
- AGIO $59.33
- GOF N/A
- AVG Volume (30 Days)
- AGIO 556.0K
- GOF 789.2K
- Earning Date
- AGIO 10-30-2025
- GOF 01-01-0001
- Dividend Yield
- AGIO N/A
- GOF 15.42%
- EPS Growth
- AGIO N/A
- GOF N/A
- EPS
- AGIO N/A
- GOF N/A
- Revenue
- AGIO $44,791,000.00
- GOF N/A
- Revenue This Year
- AGIO $23.74
- GOF N/A
- Revenue Next Year
- AGIO $159.90
- GOF N/A
- P/E Ratio
- AGIO N/A
- GOF N/A
- Revenue Growth
- AGIO 36.26
- GOF N/A
- 52 Week Low
- AGIO $23.42
- GOF $10.96
- 52 Week High
- AGIO $62.58
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- AGIO 59.88
- GOF 40.99
- Support Level
- AGIO $40.18
- GOF $12.85
- Resistance Level
- AGIO $43.81
- GOF $13.98
- Average True Range (ATR)
- AGIO 1.61
- GOF 0.46
- MACD
- AGIO -0.03
- GOF -0.06
- Stochastic Oscillator
- AGIO 77.75
- GOF 38.79
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.